SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing medical devices to treat infectious disease, announced today it has initiated a research collaboration to study the in vitro effectiveness of the Aethlon Hemopurifier® to clear the Human Immunodeficiency Virus (HIV) from blood. The studies are being conducted through a collaboration established with ImQuest Biosciences, an infectious disease research organization based in Frederick, Maryland. The studies will document the rate at which the Aethlon Hemopurifier® captures infectious forms of HIV, including multi-drug resistant strains of the virus. The studies will also identify the capture rate of gp120, a toxin shed from the surface of HIV, which causes apoptosis (programmed cell death) of immune cells. Depletion of immune cells is the hallmark of AIDS. The goal of the studies will be to reinforce and expand upon HIV data previously obtained by Aethlon researchers. In HIV care, the Hemopurifier® is targeted to fill treatment voids of concern to all HIV-infected individuals.
